论文部分内容阅读
选取32例T_2DM合并中重度OSAHS患者作为研究对象,经nCPAP治疗24周,对比治疗前后所有的空腹血糖(FBG)、血清空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、呼吸暂停低通气指数(AHI)、超敏C反应蛋白(hs-CRP)、骨形成标志物血清1型原胶原N-端前肽(P1NP)、骨吸收标志物血清1型胶原交联C-末端肽(β-CTX)及骨密度的变化。结果:nCPAP治疗24周后,患者的FINS、HOMA-IR、AHI及hs-CRP均较治疗前显著下降(P<0.05)。血清P1NP及β-CTX分别较治疗前显著降低了13.4%和13.7%,且血清β-CTX及P1NP变化值均与AHI变化值呈显著正相关(P<0.05);骨密度结果和未治疗时相比差异无明显统计学意义。结论:24周的nCPAP治疗能够降低T_2DM合并OSAHS患者的骨转换标志物水平,但对骨密度无显著影响。
Thirty-two T 2DM patients with moderate-severe OSAHS were selected as the study subjects. All the patients underwent nCPAP for 24 weeks. All fasting blood glucose (FBG), serum fasting insulin (FINS), insulin resistance index (HOMA-IR), apnea hypopnea (AHI), high-sensitivity C-reactive protein (hs-CRP), bone formation marker serum type 1 procollagen N-terminal propeptide (P1NP), bone resorption marker serum type 1 collagen cross-linked C-terminal peptide -CTX) and bone mineral density changes. Results: The levels of FINS, HOMA-IR, AHI and hs-CRP in patients after nCPAP treatment for 24 weeks were significantly lower than those before treatment (P <0.05). Serum levels of P1NP and β-CTX were significantly decreased by 13.4% and 13.7%, respectively, and the changes of serum β-CTX and P1NP were positively correlated with the changes of AHI (P <0.05). The results of BMD and untreated No significant difference compared to the statistical significance. CONCLUSIONS: 24-week nCPAP treatment reduced the level of bone turnover markers in patients with T 2DM and OSAHS but had no significant effect on bone mineral density.